WEBULL
News
PSTV
0.5115
-2.22%
-0.0116
Weekly Report: what happened at PSTV last week (1103-1107)?
Weekly Report · 4d ago
Plus Therapeutics To Present REYOBIQ And ReSPECT-LM Clinical Data On Leptomeningeal Metastases At SITC And MRF Brain Metastases Summit
Benzinga · 11/06 12:40
CFO Makes Bold Move with Major Stock Purchase in Plus Therapeutics!
TipRanks · 11/06 02:08
Plus Therapeutics CFO Andrew Sims Reports Acquisition of Common Shares
Reuters · 11/05 13:30
Buy Rating for Plus Therapeutics: Growth Potential Driven by CNSide Launch and Strategic Positioning
TipRanks · 11/03 23:15
Plus Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/03 11:41
Plus Therapeutics Price Target Cut to $2.00/Share From $3.00 by HC Wainwright & Co.
Dow Jones · 11/03 11:41
HC Wainwright & Co. Maintains Buy on Plus Therapeutics, Lowers Price Target to $2
Benzinga · 11/03 11:31
Plus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
TipRanks · 11/03 11:15
PLUS THERAPEUTICS, INC <PSTV.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $2 FROM $3
Reuters · 11/03 11:06
Weekly Report: what happened at PSTV last week (1027-1031)?
Weekly Report · 11/03 09:01
U.S. RESEARCH ROUNDUP- Crowdstrike, Guardant Health, Palantir Technologies
Reuters · 11/03 07:35
Plus Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 10/31 12:01
Plus Therapeutics Price Target Maintained With a $5.00/Share by D. Boral Capital
Dow Jones · 10/31 12:01
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
Benzinga · 10/31 11:51
Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 10/30 22:45
Plus Therapeutics GAAP EPS of -$0.04 misses by $0.01, revenue of $1.4M misses by $0.1M
Seeking Alpha · 10/30 21:13
Plus Therapeutics Q3 net loss widens
Reuters · 10/30 20:33
Plus Therapeutics Q3 EPS $(0.04) Misses $(0.02) Estimate, Sales $1.397M Miss $1.500M Estimate
Benzinga · 10/30 20:28
Plus Therapeutics Reports Q3 Net Loss of $4.4 Million on $1.4 Million Grant Revenue
Reuters · 10/30 20:16
More
Webull provides a variety of real-time PSTV stock news. You can receive the latest news about Plus Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.